HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $64 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $64 price target.
Stocks · News reference
Celldex Reports Topline Results From The Company’s Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Trials Evaluating Two Doses Of Barzolvolimab In Patients With Chronic Spontaneous Urticaria; Results Showed Rapid, Profound, Sustained Efficacy, Supporting Barzolvolimab’s Potential To Be A Transformational Therapy In CSU
EMBARQ-CSU1 and -CSU2 met primary and all key secondary endpoints at 12 weeks across both studies and both dose groupsClinically meaningful and statistically significant benefit demonstrated in omalizumab refractory CSU
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Leerink Partners Maintains Outperform on Celldex Therapeutics, Raises Price Target to $88
Leerink Partners analyst Thomas Smith maintains Celldex Therapeutics (NASDAQ:CLDX) with a Outperform and raises the price target from $70 to $88.
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $50 to $57.
Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results
U.S. stocks were mixed: Nasdaq and S&P 500 rose while the Dow fell; communication services gained, financials dropped, and Thor Industries climbed 5%.